clinical trial · NCT03299166
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
Biohaven Pharmaceuticals, Inc.·phase3·completed·n = 426
Obsessive-Compulsive DisorderTroriluzolePlacebo
brief summary
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment
started
Dec 19, 2017
primary completion
Jun 2, 2020
completion
Dec 8, 2025
last updated
Jan 22, 2026
official title
A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol